Quick Search 
Drugs of the Future
Register or sign in

Volume 36, Issue 11, November 2011, Pages 807-871
Multitargeted kinase inhibitor, Pan-BCR-ABL inhibitor, Oncolytic.
Pound, H.B., Ho, V.Q., Pinilla-Ibarz, J.
Drugs Fut 2011, 36(11): 807
Summary | Full Text: HTMLPDF 
Free fatty acid receptor FFA1 agonist, Insulin secretagogue, Treatment of type 2 diabetes.
de Lartique, J.
Drugs Fut 2011, 36(11): 813
Summary | Full Text: HTMLPDF 
Tyrosine-protein kinase JAK2 inhibitor, Receptor-type tyrosine-protein kinase FLT3 inhibitor, Treatment of myeloproliferative diseases.
Harry, B.L., Eckhardt, S.G., Jimeno, A.
Drugs Fut 2011, 36(11): 819
Summary | Full Text: HTMLPDF 
 Trastuzumab emtansine.
Tumor-activated prodrug (TAP) immunoconjungate, Oncolytic.
Kuemler, I., Mortensen, C.E., Nielsen, D.L.
Drugs Fut 2011, 36(11): 825
Summary | Full Text: HTMLPDF 
 Recombinant vector vaccines for the prevention and treatment of HIV infection
Barry, M.A.
Drugs Fut 2011, 36(11): 833
Summary | Full Text: HTMLPDF 
 GAD-65 autoantibodies and their role as biomarkers of type 1 diabetes and latent autoimmune diabetes in adults (LADA)
Towns, R., Pietropaolo, M.
Drugs Fut 2011, 36(11): 847
Summary | Full Text: HTMLPDF 
 Highlights in epilepsy research: current topics from the 136th Annual Meeting of the American Neurological Association, September 25-27, 2011.
Dhir, A.
Drugs Fut 2011, 36(11): 855
Summary | Full Text: HTMLPDF 
 Neurodegenerative disorders: an update – highlights of the 23rd Biennial Meeting of ISN-ESN 2011, August 28-September 1, 2011, Athens, Greece.
Kumar, A., Jitendriya, M.
Drugs Fut 2011, 36(11): 859
Summary | Full Text: HTMLPDF 
 Royal Society of Chemistry's 22nd Symposium on Medicinal Chemistry in Eastern England, Hatfield, UK, May 19, 2011.
Norman, P.
Drugs Fut 2011, 36(11): 867
Full Text: HTMLPDF 

© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy